In her latest On target column published by the ESMO Daily Reporter, VHIO’s Elena Garralda discusses the expanding toolbox for immuno-oncology in advanced…
ESMO24
The phase 3 open-label, randomized NIAGARA trial was designed to evaluate the benefits of adding perioperative immunotherapy durvalumab to standard…
